Drug intelligence / Profile preview

HWO-002

Development stage: Preclinical
Lead developer: Hanwha Pharma

Overview

HWO-002 is an investigational drug candidate currently in the preclinical stage of development by the South Korean company Han Wha Pharma (Hanwha Pharma). It is being developed for the treatment of endocrine disorders. As an early-stage pipeline asset, specific details regarding its chemical modality, molecular target, and mechanism of action have not been publicly disclosed by the developer. The candidate is part of Han Wha Pharma's broader research and development efforts in the metabolic and endocrine therapeutic areas.

Beyond the preview

Go deeper on HWO-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HWO-002.

Explore the full profile